Financials

  • Market Capitalization 527.6 M
  • Employee 133
  • Founded 2003
  • CEO N/A
  • Website www.sutrobio.com
  • Headquarter California, United States
  • FIGI BBG000R4V3P3
  • Industry Biotechnology
Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
-1.52
Price to sales ratio
2.23

Related tickers

#NamePrice24h %7d %1M %1Y %Market CapLast 7 Days
2864
ARVN
Arvinas, Inc. - Common Stock
8.55 USD-0.47%+4.27%+18.42%-8.06%551.66 M USD
2871
STTK
Shattuck Labs, Inc. - Common Stock
6.90 USD-4.96%+5.99%+69.12%+731.33%529.10 M USD
2913
PRTA
Prothena Corporation plc - Ordinary Shares
9.85 USD+1.76%+2.50%+15.07%+49.92%515.68 M USD
2923
ZURA
Zura Bio Limited - Class A Ordinary shares
5.49 USD+8.07%+9.80%+52.50%+346.34%521.54 M USD

Frequently asked questions about Sutro Biopharma, Inc. - Common Stock

What is the Sutro Biopharma, Inc. - Common Stock stock price today?

The current price of Sutro Biopharma, Inc. - Common Stock (STRO) is 31.84. Over the past 24 hours, the stock has changed by -0.90%. Follow the STRO chart for real-time price dynamics.

What is the stock ticker of Sutro Biopharma, Inc. - Common Stock?

Sutro Biopharma, Inc. - Common Stock trades under the ticker STRO. Tickers can differ by exchange, so always check the exchange and instrument details before trading.

Is Sutro Biopharma, Inc. - Common Stock stock going up?

STRO has changed by +5.29% over the last week, +22.27% over the last month, and +83.09% over the last year. Review the chart to see whether the current move is part of a broader trend.

What was Sutro Biopharma, Inc. - Common Stock net income for the last quarter?

Sutro Biopharma, Inc. - Common Stock reported net income of -38.48 M for the last quarter. The previous quarter showed -46.76 M, which means net income changed by +17.70%.

How many employees does Sutro Biopharma, Inc. - Common Stock have?

As of the latest available data, Sutro Biopharma, Inc. - Common Stock has 133 employees. Workforce size can provide additional context about the company's scale and operations.

What is Sutro Biopharma, Inc. - Common Stock EBITDA?

Sutro Biopharma, Inc. - Common Stock EBITDA is -28.38 M, and its EBITDA margin is -195.4%. EBITDA is commonly used to evaluate operating performance before interest, taxes, depreciation, and amortization.

How can I buy Sutro Biopharma, Inc. - Common Stock stock?

You can buy Sutro Biopharma, Inc. - Common Stock (STRO) through a broker that provides access to the relevant stock exchange. Before trading, check commissions, execution conditions, account type, and whether the stock fits your investment plan.

Should I invest in Sutro Biopharma, Inc. - Common Stock stock?

Investing in Sutro Biopharma, Inc. - Common Stock requires reviewing its financial statements, valuation, earnings outlook, news, technical picture, and market risks. Use the STRO chart and related analysis on metatrader.com as part of your research.

Sutro Biopharma, Inc. - Common Stock

Sutro Biopharma, Inc. is a publicly traded biotechnology company headquartered in South San Francisco, California focused on clinical-stage drug discovery, development and manufacturing. Using a proprietary cell-free protein synthesis platform, Sutro is working on oncology therapeutics using protein engineering and rational design. Founded in 2003 under the name Fundamental Applied Biology, the company name changed to Sutro Biopharma in 2009. William Newell, CEO as of 2024, joined Sutro in January 2009. Sutro's cell-free protein synthesis and site-specific conjugation platform, XpressCF+, contributed to the discovery of STRO-001 and STRO-002, internally-developed antibody drug conjugates, or ADCs. STRO-001 is an ADC targeting CD74, a protein highly expressed in multiple myeloma and non-Hodgkin's lymphoma, and is currently in a Phase I clinical trial. STRO-002 is an ADC targeting folate receptor alpha, a cell-surface protein highly expressed in gynecological cancers.

News